Revenue included license revenue of $17.4M for the quarter ended March 31, 2025, related to the collaboration and licensing agreement with Kaken. Assuming successful close of the merger with ACELYRIN, the combined company’s pro forma cash position of approximately $737M as of December 31, 2024 is expected to provide runway to advance its pipeline through multiple planned key clinical data readouts and to fund operating expenses and capital expenditure requirements into 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Acelyrin stockholders approve merger agreement with Alumis
- Alumis stockholders approve merger agreement with Acelyrin
- Largest borrow rate increases among liquid names
- Acelyrin urges stockholders to vote for proposed merger with Alumis
- Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition